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Abstract 
Chronic Myeloid Leukaemia (CML) is maintained by a rare population of tyrosine 
kinase inhibitor (TKI) insensitive malignant stem cells. Our long term aim is to 
find a BcrAbl-independent drug that can be combined with a TKI to improve 
overall disease response in chronic phase CML.  Omacetaxine mepesuccinate, a 
first in class cetaxine, has been evaluated by clinical trial in TKI-
insensitive/resistant CML.  Omacetaxine inhibits synthesis of anti-apoptotic 
proteins of the Bcl-2 family including Mcl-1, leading to cell death.  
 
Omacetaxine effectively induced apoptosis in primary CML stem cells 
(CD34+38lo) by down regulation of Mcl-1 protein.  In contrast to our previous 
findings with TKIs, omacetaxine did not accumulate undivided cells in vitro. 
Furthermore, the functionality of surviving stem cells following omacetaxine 
exposure was significantly reduced in a dose dependent manner as determined 
by colony forming cell and the more stringent long-term culture initiating cell 
colony assays. This stem cell directed activity was not limited to CML stem cells 
as both normal and non-CML CD34+ cells were sensitive to inhibition. Thus, 
although, omacetaxine is not leukaemia stem cell specific, its ability to induce 
apoptosis of leukaemic stem cells distinguishes it from TKIs and creates the 
potential for a curative strategy for persistent disease.  
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Introduction 
 
Omacetaxine mepesuccinate (ChemGenex Pharmaceuticals), a first in class 
cetaxine, is a semi-synthetic alkaloid that has demonstrable activity in clinical trial 
in acute myeloid leukaemia (AML), myelodysplastic syndrome (MDS), as well in 
chronic myeloid leukaemia (CML)(1). However, with the continued success of 
tyrosine kinase inhibitors (TKI), such as imatinib, nilotinib and dasatinib, as first 
and second line treatment for CML, the role of omacetaxine has been restricted 
to niche indications including failure of two or more TKI or with the TKI-insensitive 
mutation, T315I, against which all currently licensed TKI are ineffective.  
Omacetaxine is a semisynthetic, subcutaneously bioavailable form of 
homoharringtonine (HHT). HHT was used in second line therapy for those CML 
patients in the pre-TKI era of the 1990s who failed interferon α therapy and were 
ineligible for a transplant(2)   (3). Therefore this product has, for a second time, 
become a valuable option in the treatment of resistant disease. Moreover, the 
demonstration that omacetaxine can kill leukaemic stem cells in murine 
models(4) has allowed the drug to be considered as a therapeutic option for both 
persistent and resistant, disease. 
 
HHT, from here in referred to as omacetaxine, is derived from various 
Cephalotaxus species (Chinese yew tree), and was first discovered by the 
Chinese to have natural anti-tumour and anti-leukaemic properties in the 
1970s(5, 6).  Recent work has elucidated a mechanism of action targeted to the 
A-site cleft of eukaryotic ribosomes (7) resulting in transient inhibition of protein 
synthesis of short-lived proteins such as myeloid cell leukaemia (Mcl-1) protein (a 
highly expressed member of the Bcl-2 family of anti-apoptotic proteins) leading to 
apoptosis(8). Further, it has been shown that Mcl-1 plays a critical role in the 
survival of leukaemia cells and its expression is up-regulated with respect to 
normal(9, 10). As such omacetaxine acts independently of BcrAbl kinase activity, 
the causative oncoprotein in CML. Taken together with a recently reported ability 
to kill stem cells(4), omacetaxine could therefore be an interesting therapeutic 
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modality in minimal residual disease in CML where the continued detection of 
BcrAbl transcripts is thought to originate from the stem cell compartment(11) and 
leukaemic stem cell survival may be BcrAbl independent(12). 
 
Therefore the aim of our study was to assess the activity of omacetaxine against 
CML stem/progenitor cells in vitro in order to identify potential ways of eradicating 
persistent disease.  Sequential clinical samples from newly diagnosed cases 
were selected for assay and were not subject to mutation analysis.  We have 
previously shown CML CD34+ cells to be insensitive to TKI by virtue of their 
quiescence and primitive phenotype.  From our on-going work and that of others, 
it is our belief that CML stem cells may not be oncogene addicted (that is 
depdendent on BcrAbl for their survival), and thus any novel agents or novel 
indications for existing molecules with targeting potential at the (stem) cell level 
to complement TKI modalities is of significant interest. 
 
Materials and methods 
 
Reagents 
Omacetaxine mepesuccinate, supplied by ChemGenex Pharmaceuticals, Inc., 
Menlo Park, CA, USA, was stored lyophilised at room temperature; once 
reconstituted in saline to 10mM, the stock solution was stored at 4°C for up to 3 
months.  
 
Cell culture 
Primary CML cells were obtained with informed consent from leukapheresis 
samples of newly diagnosed patients with chronic phase CML or Ph- 
haematological disorders (e.g. lymphoma) as controls. CD34+ cells enriched by 
positive selection (CliniMACS, Miltenyi Biotec Ltd) according to the 
manufacturer’s instructions to >95 % purity were cryopreserved in 10% (v/v) 
DMSO in 4% (w/v) ALBA (human albumin solution, Scottish National Blood 
Transfusion Service, Edinburgh, UK) and stored in the vapour phase of liquid 
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nitrogen until required.  CD34+ cells were cultured in Serum Free Media (SFM) 
comprising Iscove’s modified Dulbecco’s medium (IMDM) with BIT (bovine serum 
albumin, insulin, transferrin; Stem Cell Technologies, Vancouver, Canada), 
1mmol/L glutamine, 1mmol/L streptomycin/penicillin, 40ng/mL low density 
lipoprotein (LDL) and 0.1mmol/L 2-mercaptoethanol (all Invitrogen Ltd, Paisley, 
UK) further supplemented with a 5 growth factor (5GF) cocktail as previously 
described(13).  
 
The BcrAbl positive human myeloid cell lines, K562 and KCL22 were maintained 
in RPMI 1640 (Sigma-Aldrich) supplemented with 10% (v/v) fetal calf serum 
containing 1mmol/L each of streptomycin, penicillin and glutamine (RPMI+). Total 
cell counts and viability was assessed using the trypan blue dye exclusion 
method.  
 
Flow Cytometry 
Apoptosis 
To assess apoptosis after drug treatment an aliquot of cell suspension containing 
1 to 2x105 cells was removed for staining with Annexin V-FITC and Viaprobe (BD 
Biosciences, Oxford, UK) as per the manufacturer’s instructions and analysed by 
flow cytometry using a BD FACS Canto with Diva software. Cells undergoing 
apoptosis initially become Annexin V positive (early apoptosis) and as apoptosis 
progresses, become positive for both Annexin V and Viaprobe (late apoptosis).   
 
Cell division tracking   
Upon recovery from liquid nitrogen, CML CD34+ cells were stained with 1µM 
carboxy-fluorescein diacetate succinimidyl diester (CFSE; Molecular Probes, 
Invitrogen Ltd, Paisley, UK) as described previously in detail(14). Cells were then 
cultured in SFM+5GF in the presence or absence of omacetaxine for 24 or 72h. 
After 3 days cells were harvested, total cell viability assessed, and an aliquot of 
cells from each treatment stained with anti-CD34-PE antibody (BD Pharmingen, 
Oxford, UK) for flow cytometry analysis. Cells cultured with 100ng/mL Colcemid 
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(Invitrogen), which arrests cell cycle progression, were used to identify the 
undivided (CFSEmax) cell population.  
To measure the overall effect of the treatments on cell survival and the number of 
undivided cells remaining after culture with omacetaxine, the percentage 
recovery of CD34+ cells in the undivided CFSEmax peak was calculated with 
respect to the input as previously described (13) and expressed as a proportion 
of the No Drug Control (NDC).  Briefly, the number of CD34+ cells used to 
establish each culture was recorded. After the 3-day culture period, the total 
number of viable cells harvested from each culture condition was recorded, as 
were the percentages of viable CD34+ cells found in the undivided fraction and in 
each division peak from the CFSE/CD34+ flow cytometry plots. Percentage 
recovery of input cells in each peak could then be calculated by dividing the 
absolute number of CD34+ viable cells in each peak on day 3, corrected for cell 
division, by the total number of input CD34+ cells and multiplying by 100.  Note, 
although the percentage in the CFSEmaxCD34+ peak may increase with 
omacetaxine treatment, because of a very significant reduction in total cells 
(undivided plus proliferating cells), the absolute number of undivided cells 
(product of % x total cell number) may remain unchanged. 
 
Primitive subsets 
The CD34+ enriched cells were stained with anti-CD34-APC and anti-CD38-PE 
antibodies before cell sorting using a FACS Aria (Becton Dickinson) into three 
populations: CD34lo38+ (mature), CD34+38+ (progenitor) and CD34+38lo 
(primitive).  The CD34+38lo fraction approximates the most primitive quiescent 
stem cell QSC pool (< 5% total CD34+ cells).  Cells were analysed using a BD 
FACS Canto instrument with Diva software. 
 
Colony forming cell (CFC) and long term culture-initiating cell (LTC-IC) 
After culture in omacetaxine for 24 or 72h, CD34+ cells remaining were set up in 
CFC and LTC-IC assays to assess the proliferative potential of cell populations 
remaining after drug treatment. For CFC assays, 2.5x103 cells were added to 
 7 
1.5mL Methocult (Stemcell  Technologies, Vancouver, BC) in duplicate 35mm 
culture dishes and cultured for 12 to 14 days at 37°C in a 5% CO2 humidified 
incubator. 
 
LTC-IC assays were set up as previously described(15). Briefly, M2-10B4 cells 
and SL/SL fibroblasts were established as feeder layers then irradiated at 80Gy. 
CML cells remaining in culture after drug treatment were washed 3 times and 
then plated in duplicate on the irradiated feeder layers in Myelocult medium 
supplemented with hydrocortisone at a final concentration of 1µM (Stem Cell 
Technologies). Cultures were maintained for 5 weeks with weekly half medium 
changes. After 5 weeks, cells were counted and 2.5x104 cells were transferred to 
CFC assays and maintained in culture for a further 2 weeks in Methocult medium 
before the colonies were counted.   
 
Western blotting 
Following treatment with drugs, K562 and primary CML cells (2 to 5x106) were 
pelleted by centrifugation, washed twice with ice cold PBS and then lysed in 
buffer containing 50mM Tris-HCl pH 7.4, 150mM NaCl, 1% Nonidet P-40, 1mM 
ethylene diamine tetra-acetic acid (EDTA), plus protease inhibitors (Complete 
mini protease inhibitor cocktail tablets; Roche Diagnostics, Burgess Hill, UK). 
Protein lysates were separated on 4 to 15% Tris-HCl gradient gels (Bio-Rad 
Laboratories, Hemel Hempstead, Hertfordshire, UK), transferred onto 
nitrocellulose membrane (Bio-Rad Laboratories) and blocked with 5% bovine 
serum albumin (BSA) in Tris-buffered saline (TBS)-0.1% Tween 20 (TBS-T) for 
1h at room temperature (RT).  Membranes were incubated with primary antibody 
overnight at 4ºC: Poly(ADP-ribose) polymerase (PARP), Myeloid cell leukaemia 
(Mcl-1), GAPDH  (Cell signalling, New England Biolabs (UK) Ltd, Hertfordshire, 
UK) abl, Bcl-2, Bcl-2 interacting mediator of cell death (Bim) (BD Biosciences, 
Oxford, UK) at 1:1,000 and anti-heat shock protein 90 (HSP90) (R&D systems, 
Abingdon, UK) at 1:10,000 in 1% BSA/TBS-T. Membranes were then washed 5 
times with TBS-T and then incubated with horse radish peroxidase-labelled 
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secondary antibody at 1:3,000 in 1% BSA/TBS-T for 1h at RT. Antibody detection 
was performed using enhanced chemiluminescence (ECL) reagent (Immun-
Star™ Western C™Kit, Bio-Rad) and visualised in a ChemiDoc illuminator (Bio-
Rad Laboratories) with Quantity 1 image capture software. 
 
Results 
Omacetaxine potently inhibits growth of K562, primary CML CD34+ and 
non-CML CD34+ cells in vitro 
The drug concentration required to reduce cell numbers to 50% of the NDC (IC50) 
was determined by viable cell counts for K562, CML CD34+ and non-CML CD34+ 
cells at 24 hourly intervals over three days (Figure 1). The mean IC50 values for 
omacetaxine treated K562 in three independent experiments were >1000, 35 and 
35nM at 24, 48 and 72h, respectively (Figure 1a).  Primary CML CD34+   cells 
were more sensitive to omacetaxine treatment than K562 with IC50 values of 40, 
4 and 2.8nM at 24, 48 and 72h, respectively (n=3; Figure 1b).   The omacetaxine 
effect appeared to be stem/progenitor cell directed as it produced similar IC50 
values of 20, 4.5 and 3.5nM at 24, 48 and 72h, respectively, with non-CML 
CD34+   cells (n=2; Figure 1c). 
 
The minimum exposure to omacetaxine required to inhibit cell growth by 
>50% and induce apoptosis in CD34+ cells is 24h 
CML CD34+ cells were cultured with and without omacetaxine in SFM+5GF for 
various time-points from 15min to 72h (Figure 2), after which cells were washed 
free of drug and re-seeded in fresh SFM+5GF. Omacetaxine was used in this 
experiment at 10 and 100nM being in the approximate range of the calculated 
IC50 values (Figure 1) and clinically achievable concentrations (Personal 
communication with ChemGenex).  Cells were counted after a total of 72h in 
culture for all samples and stained with Annexin V / Viaprobe to measure 
apoptosis. Total viable cells were expressed as trypan blue cell counts multiplied 
by the percentage cells which were negative for Annexin V / Viaprobe.  
Treatment of CML CD34+   cells with 100nM omacetaxine for only 6h reduced 
 9 
viable cell numbers at 72h to 50% of NDC. However a minimum of 24h exposure 
to either 10 or 100nM omacetaxine was required to significantly reduce viable 
cell numbers to greater than 50% with respect to 15min drug treatment (Figure 
2a; p<0.001; n=3) (as NDC had been normalised to 100% in each experiment, 
there was no deviation and therefore statistics were generated with respect to the 
next time-point). Omacetaxine (100nM) effectively induced apoptosis in CML 
CD34+ cells after just 24h treatment in 58% of cells as measured by the total 
cells staining positive for Annexin V at 72h, however prolonged 72h drug 
treatment at this concentration resulted in almost all cells (90%) undergoing 
apoptosis (Figure 2b). CD34+ cells from a myeloma patient (non-CML control) 
that had been treated with 10nM omacetaxine for 24h, reduced in viable cell 
count to only 17% of the NDC (Figure 2c) and to a similar degree to CML CD34+ 
cells, again suggesting a stem/progenitor cell directed effect of the drug.  
Treatment of non-CML CD34+ cells induced similar levels of apoptosis as for 
CML (Figure 2d).  
 
Omacetaxine does not accumulate cells in the undivided fraction 
Although omacetaxine was clearly inducing apoptosis in CML CD34+ cells in 
vitro, an effect not observed with TKIs(13, 16, 17), we next sought to determine if 
omacetaxine was anti-proliferative against the stem/progenitor cell compartment, 
leading to arrest of cell cycle progression or block of cell division in a proportion 
of cells without killing.  This was done using flow cytometry with CFSE staining to 
facilitate analysis of cell division history(14). Although there was an increase in 
the percentage of cells remaining alive in the undivided fraction (e.g. 30% with 
100nM omacetaxine; Fig 3a) with increasing omacetaxine concentration, at 24h 
there was a dose dependent significant reduction in the total number of CD34+ 
cells recovered with respect to the NDC (Figure 3c(i), *p<0.05, ***p<0.001).   The 
fold-change in recovery of input of undivided CD34+ cells is calculated as the 
product of the percentage in the undivided gate (which has increased) times the 
total CD34+ cell number (which has decreased through apoptosis). There was no 
statistically significant change in CML CD34+ cells recovered in the undivided 
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fraction with respect to NDC with omacetaxine at any of the concentrations 
tested (Figure 3d(i)). Although only assayed once in normal G-CSF mobilised 
donor cells, more CD34+ cells were recovered in all divisions as a percentage of 
the NDC in comparison to CML with 10 or 50nM but not 100nM omacetaxine (Fig 
3c(ii)); moreover, fewer cells were recovered in the undivided fraction in a dose 
dependent manner relative to NDC (Fig 3d(ii)) as compared to CML (Fig 3d(i)). 
 
Omacetaxine and stem/progenitor cell functionality 
Although, encouragingly, it appeared that omacetaxine activity in vitro was 
stem/progenitor cell directed, in that the drug reduced total CD34+ cell numbers, 
we were interested to know the stem/progenitor cell function of any remaining 
apparently viable CD34+ cells following treatment.  This was assessed in CFC 
and LTC-IC assays. CFC assays demonstrated that omacetaxine significantly 
reduced the number of CML and non-CML CFC, in a dose dependent manner 
with respect to the NDCs (Figure 4a, ***p<0.001). We were also able to confirm 
in a single sample of normal G-CSF mobilised donor CD34+ cells that 
omacetaxine at high concentration (50 and 100nM) was cytotoxic for CFC activity 
to a similar degree as for CML cells.  
 
CFC assays give an indication of committed progenitor cell survival but for stem 
cell enumeration, LTC-IC assays are more appropriate.  Mirroring the CFC result, 
omacetaxine reduced the LTC-IC number in CML, non-CML and normal donor 
CD34+ cells after 24h exposure (Figure 4b).  
 
Scheduled combination of omacetaxine with imatinib improves cell kill in 
Ph+ cell lines 
The Ph+ blast crisis cell line, KCL22 was significantly more sensitive to 
omacetaxine than to imatinib (p<0.05; Figure 5a(i)). Scheduled combination of 
omacetaxine (20nM, approximate IC50) with imatinib (0.5µM) with or without drug 
washout at 24h significantly reduced cell viability with respect to omacetaxine 
alone when omacetaxine was administered before imatinib  (p<0.05; Figure 
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5a(i)).  Addition of imatinib first did not achieve increased cell kill with respect to 
omacetaxine alone. Simultaneous treatment with omacetaxine and imatinib for 
72h was no more effective than omacetaxine alone. 
In order to determine any combination effect in primary CD34+ cells, we selected 
the lowest concentration of omacetaxine (10 nM) as this had shown lesser 
toxicity by CFC in the normal CD34+ sample tested previously [Figure 4a]. CML 
CD34+ cells were treated with omacetaxine or imatinib (5µM) or both in 
combination. When administered together, all of the combinations tested were 
significantly more effective than treatment with either imatinib (p<0.001) or 
omacetaxine alone (p<0.05; Figure 5b(i)).   In contrast to KCL22, treatment of 
primary CD34+ cells with omacetaxine and imatinib for 72h was equally effective 
whether administered simultaneously or in a scheduled combination (Figure 5b(ii 
& iii). By cell count, apoptosis and colony forming potential, normal donor CD34+ 
cells were as sensitive as CML CD34+ cells to treatment with omacetaxine alone 
or in combination with imatinib.  
  
Mechanism of action of omacetaxine in Ph+ cells 
Increasing concentrations of omacetaxine induced apoptosis in K562 and CML 
stem/progenitor cells as confirmed by PARP cleavage and loss of the anti-
apoptotic protein, Mcl-1 (Figure 6a).   K562 cells are known to have extremely 
low expression of Bcl-2(18) and indeed we did not detect this protein by Western 
blotting of lysates from this cell line but it was found to be unchanged in primary 
CML CD34+ cells with omacetaxine treatment (Figure 6b). Likewise, both the pro-
apoptotic Bim protein and the molecular chaperone, HSP90 were unaffected by 
omacetaxine treatment as determined by densitometric analysis of Western blots 
with respect to the loading control (GAPDH).  HSP90 had previously been shown 
to be lost on omacetaxine treatment in Ph+ cell lines(4) together with loss of 
BcrAbl protein which we did not observe. 
 
Omacetaxine induces apoptosis of primitive CML CD34 cell subsets with 
reduction in Mcl-1 expression 
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It was of interest to determine the activity of omacetaxine in more primitive 
subsets of CD34+ cells.  To achieve this, total CML CD34+ cells were sorted by 
flow cytometry into three cell fractions (mature CD34lo38+, CD34+38+ progenitors 
and the more primitive CD34+38lo population).  As can be seen in Figure 7, even 
the more primitive CD34+38lo cells that we have previously shown to be 
insensitive to TKI like imatinib were not spared by omacetaxine, with levels of 
apoptosis in the same order as mature and progenitor cells (Figure 7a).  
Apoptosis was confirmed by cleavage of PARP (Figure 7b) and was mediated in 
the same way as in bulk CD34+ by Mcl-1 down-regulation (cf Figure 6).  
 
Discussion 
 
Our interests in CML leukaemic stem cell survival in the face of complete BcrAbl 
kinase inhibition has led us to investigate other agents which exhibit activity at 
the stem/progenitor cell level and have a mechanism of action that is BcrAbl 
independent.  We considered omacetaxine to be worthy of further investigation 
with its BcrAbl independent mechanism of action, acceptable safety in humans 
and potential for stem cell activity(4).  
 
The semi-synthetic orthologue of the natural phytochemical, HHT, omacetaxine 
was awarded ‘Fast Track’ status by the Food and Drug Administration (FDA) in 
late 2006 for those CML patients who fail imatinib or have demonstrable T315I 
BcrAbl mutation in which the drug has, rather uniquely, proven activity.  A 
number of Phase I/II clinical trials or case reports have emerged describing 
disappearance of T315I-BcrAbl transcripts with omacetaxine therapy(19, 20), 
although as might be expected cytogenetic responses were poorer in comparison 
to the efficacy of TKI in newly diagnosed patients(20, 21).  
 
Omacetaxine is targeted to the A-site cleft of eukaryotic ribosomes(7). Following 
exposure to this translation elongation inhibitor, transient inhibition of protein 
synthesis of short-lived proteins, such as Mcl-1, leads to apoptosis.  Leukaemia 
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cells, and specifically CML cells, may be more Mcl-1 dependent for survival and 
therefore sensitive to the activity of omacetaxine(9).  We confirmed the down-
regulation of Mcl-1 in K562 cells and moreover, primary CML CD34+ cells in 
response to omacetaxine which precipitated caspase dependent apoptosis as 
demonstrated by PARP cleavage.   Furthermore, omacetaxine induced apoptosis 
in primitive CD34+ subsets (CD34+38lo), an effect not observed with TKI.  In 
addition, primary CML cells were found to be more sensitive to omacetaxine than 
K562 blast crisis cells with a significantly lower IC50 in the former 
 
Despite the evidence of efficacy from clinical trial and the known molecular mode 
of action of omacetaxine, it was only reported very recently(4) that the drug could 
eliminate >90% of leukaemia stem cells in murine models of BcrAbl+ CML and B-
ALL, whereas TKI (imatinib or dasatinib) achieved less than 25% kill.  
Interestingly, the kill was seen for both wild-type and T315I mutant-BcrAbl. This 
is a significant result which needs verification in primary material derived from 
CML patients as cellular context of BcrAbl expression (de novo expression in 
human stem cells versus retroviral transduction of bone marrow cells from 5-FU 
treated donor mice) may be significant given the survival mechanisms that may 
be invoked by stem cells programmed to stay alive. 
 
In an in vitro drug combination study in CML cell lines(22) it had been suggested 
that cytosine arabinoside (Ara-C) or omacetaxine might act synergistically with 
imatinib in the case of resistance to imatinib.  However, we(16) demonstrated at 
the stem cell level in vitro, that Ara-C was anti-proliferative in combination with 
imatinib resulting in accumulation of stem cells. In our current study we did not 
assay omacetaxine in combination in primary CML CD34+, but uniquely 
demonstrated apoptosis in the primitive (CD34+38lo) leukaemic cell 
subpopulation.  Thus the prevention of colony formation by omacetaxine 
observed by Tipping et al is most likely the result of CFC loss through death as 
opposed to cell cycle arrest.  Of note, if omacetaxine was to be combined with 
imatinib then there is evidence to suggest that the sequence of exposure would 
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be critical.  In one previous study antagonism was seen with the simultaneous 
combination(23) in clonogenic assays.  However this could be reverted to a co-
operative effect if omacetaxine was pulsed for 24h before imatinib. Indeed we 
have shown in a relatively less imatinib-sensitive cell line (KCL22)(24) to 
corroborate this latter finding suggesting that when introduced into the culture 
before imatinib, omacetaxine is indeed more lethal than the reverse sequence. 
As omacetaxine is likely to block accumulation of Bim which is critical to 
imatinib’s induction of apoptosis(25), this may explain the antagonism seen with 
simultaneous addition of the two drugs(23). However the loss of the Bim negative 
regulator, Mcl-1, on omacetaxine treatment may sensitise the cells to the 
combined effect of both drugs. Both simultaneous and scheduled permutations of 
the combination showed parity in toxicity between CML and normal donor CD34+ 
cells (Figure 5) at the concentrations selected to be tested. Thus, our results 
support the BcrAbl-independent stem cell directed effect of omacetaxine but 
predict toxicity in vivo owing to the non-selective killing of both normal and 
leukaemic cells which is unlikely to be abrogated through scheduled dosing 
regimens. 
 
Combinations aside, it is clear from this study that omacetaxine has activity at the 
primary CML leukaemia stem/progenitor cell level in vitro.  Samples were 
consecutive newly diagnosed cases of CML in chronic phase, in whom TKI-
resistant mutations are extremely rare and never dominant in the stem cell 
compartment prior to evolution under TKI-selection pressure.  This may mean 
that omacetaxine has a potential role in eradicating minimal residual disease 
achieved in response to TKI but maintained by persistent, as opposed, to overtly 
resistant leukaemia stem cells. The shortcoming for this agent is toxicity to 
normal stem cells which could be predicted from on-going clinical trials in which 
myelosuppression is a significant issue.  Indeed in vitro toxicity of omacetaxine to 
Ph- HSC is reported here. The paucity of results in normal donor stem cells is in 
keeping with the ethical concerns surrounding prolonging stem cell collections for 
the purposes of research from healthy individuals over and above the required 
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clinical dose, hence the decision to assay more readily available Ph- non-CML 
CD34+ cells from diseases in which the HSC is not implicated.   
 
A number of reports have been made recently demonstrating stem cell activity of 
novel agents for use in CML (e.g. farnesyl transferase inhibitors (e.g. BMS-
214662)(15), histone deacetylase inhibitors (HDACi e.g. LBH589) (26), 
autophagy inhibitors (e.g. chloroquine)(27), proteasome inhibitors (e.g. 
bortezomib)(28)).  Clearly there is considerable interest in the field to uncover a 
suitable partner to kinase inhibition to think in terms of cure for CML. 
Omacetaxine however, is the most advanced in its clinical development.  
Omacetaxine effectively induces apoptosis in primary CML stem cells through 
down regulation of Mcl-1 and independent of BcrAbl.  This mechanism of action 
could explain at least some of its clinical activity and allow omacetaxine to be 
considered as an option in the management of minimal residual disease in CML. 
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Figure Legends 
 
Figure 1 
The inhibitory effect of omacetaxine on growth of K562, CML CD34+ and 
non-CML CD34+ in vitro. The IC50 values for omacetaxine, as indicated by the 
horizontal dotted lines on the line graphs, were determined by counting viable 
cells by trypan dye exclusion in the BcrAbl blast crisis cell line K562 (a), primary 
CML CD34+ cells (b) and non-CML CD34+ cells (c) at 24 hourly intervals over 
three days. Results represent the mean of 3 separate experiments (±SEM) using 
either the K562 cell line or CD34+ cells from CML and non-CML patients (Ewing’s 
Sarcoma and Multiple Myeloma). All counts were done in duplicate.  
 
Figure 2 
Determination of the minimum exposure time to omacetaxine required to 
inhibit cell growth and induce apoptosis in CML CD34+ cells. CML CD34+ 
cells were cultured with and without omacetaxine at 10nM (grey bars) or 100nM 
(white bars) in SFM+5GF for the time-points indicated, after which cells were 
washed free of drug, re-seeded in fresh SFM+5GF and counted at 72h. Total 
viable cells were determined as trypan blue cell counts multiplied by the 
percentage of cells which were negative for Annexin V/Viaprobe, and expressed 
as a percentage of the no drug control (NDC) (a & c). Percentage of cells 
undergoing apoptosis (sum of Annexin V+ in lower right [LR] quadrant of FACS 
plot plus Annexin V/Viaprobe double positive in upper right [UR] quadrant) are 
also displayed for CML (b) and non-CML (Multiple Myeloma) (d). Results in (a) 
and (b) are the mean of 3 independent experiments using 3 individual CML 
patient samples (±SEM).  
 
Figure 3 
Effect of omacetaxine on dividing versus non-dividing cells. Representative 
histogram plots for CD34+ cells from one CML patient (a) and one normal G-CSF 
mobilised donor (b) showing CFSE fluorescence in cells remaining at 72h after 
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treatment in the first 24h with (i) 5GF alone, (ii) 10nM omacetaxine or (iii) 100nM 
omacetaxine, and the overlay of all three plots in panel (iv). Dot plots below each 
histogram illustrate CFSE (x-axis) with CD34+   (y-axis) expression in the same 
samples.  The viable cells that are undivided (CD34+CFSEmax) remaining in each 
treatment is indicated by the box.  (c) Total recovery of CD34+ cells in all 
divisions with respect to input cells for (i) CML (n=4) and (ii) normal (n=1) CD34+ 
cells treated with omacetaxine for 24h and analysed by flow cytometry at 72h. 
Data are expressed as a percentage of NDC. Omacetaxine treatment 
significantly reduced the total CD34+ cells recovered in a dose dependent 
manner with respect to the NDC (*p<0.05, ***p<0.001).(d) The fold change in 
recovery of undivided (CD34+CFSEmax) cells after 24h treatment with 
omacetaxine was calculated. The calculated percentage recovery in the NDC 
was normalised to 1 arbitrary unit and each drug treatment scaled accordingly to 
give fold-change in (i) CML (presented as mean ± SEM) and (ii) normal CD34+ 
cells treated with omacetaxine. There was no significant increase in the number 
of CML CD34+ cells recovered in the undivided fraction following omacetaxine 
treatment of any concentration relative to input. 
 
Figure 4 
The clonogenic and stem cell capacity of cells remaining after omacetaxine 
treatment 
(a) CFC: CD34+ cells were cultured ± omacetaxine in SFM+5GF as indicated 
after which time cells were washed free of drug and added to semi-solid culture 
media to assess colony forming capacity as described in the Materials and 
methods. Colonies were counted and are expressed as a percentage of the NDC 
for (i) CML (n=4), (ii) non-CML (n=2: Multiple Myeloma and Mantle Cell 
Lymphoma) and (iii) normal G-CSF mobilised donor (n=1). Omacetaxine 
significantly reduced the colony forming potential of CML and non-CML stem 
cells, in a dose and time-dependent manner with respect to the NDC (***p< 
0.001) and also reduced colony formation in normal stem cells.  (b) LTC-IC: 
CD34+ cells remaining after omacetaxine treatment as in (a) were cultured for 5 
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weeks on stroma then plated out in CFC as described in the Materials and 
methods. Total colonies were counted for (i) CML (n=2), (ii) non-CML (n=2), and 
(iii) normal CD34+ (n=1). 
 
Figure 5 
Effect of scheduled combination of omacetaxine with imatinib in Ph+ cell 
lines and primary CML CD34+ cells 
(a) The number of viable KCL22 cells remaining after culture for a total of 72h  
with omacetaxine (20nM) ± imatinib (0.5µM) was determined by trypan blue 
staining (i) KCL22 cells were significantly more sensitive to treatment with 
omacetaxine than to imatinib (p<0.05). All combinations were better than imatinib 
alone. When omacetaxine was administered before imatinib, cell number was 
significantly reduced with respect to treatment with omacetaxine alone (p<0.05).  
(ii) The percentage of cells undergoing apoptosis is also displayed for the various 
treatment arms. Results are the mean of 3 independent experiments (±SEM). 
(b) CML CD34+ cells were treated with omacetaxine (10nM) ± imatinib (5µM) or 
in combination as illustrated. (i) All of the combinations tested were significantly 
more toxic than treatment with either imatinib (p<0.001) or omacetaxine alone 
(p<0.05).   (ii) Treated cells were stained with Annexin V to measure apoptosis or 
(iii) washed free of drug and added to semi-solid culture media for measurement 
of colony formation as described in the Materials and methods. Colonies are 
expressed as a percentage of the NDC. Omacetaxine + imatinib was equally 
effective whether administered simultaneously or with omacetaxine introduced 
24h before imatinib for 48h. Results are the mean of 3 independent experiments 
using 3 individual CML patient samples (±SEM) except for the CFC assay where 
n=2.  
(c) Normal donor CD34+ cells (n=1) were cultured and treated with omacetaxine 
and/or imatinib as for CML CD34+ cells. (i) Cell counts (ii) apoptosis and (iii) 
colony forming potential of cells remaining after treatment showed that normal 
CD34+ cells were as sensitive to treatment with omacetaxine alone or in 
combination with imatinib as CML CD34+ for all of the treatment arms tested.  
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Figure 6 
Apoptotic protein expression after 24h omacetaxine treatment. 
(a) Exposure to omacetaxine for 24h induced apoptotic signalling in (i) K562 cells 
and (ii) CML CD34+ cells as shown by cleavage of PARP and reduction in Mcl-1 
protein levels in a dose dependent manner. Levels of anti-apoptotic protein Bcl-2 
remained unchanged following omacetaxine treatment of CML stem cells but 
were absent in the CML cell line K562.   Expression levels were normalised 
against GAPDH loading control by densitometric analysis.  (b) 24h treatment with 
omacetaxine did not change expression of HSP90, BcrAbl or Bim proteins in (i) 
K562 or (ii) two CML CD34+ samples.  
 
Figure 7 
Apoptotic protein expression in primary CML CD34+ subpopulations after 
omacetaxine treatment 
(a)(i) Measurement of apoptosis by Annexin V/Viaprobe staining in sorted cell 
fractions (CD34lo38+ (white bars), CD34+38+ (grey bars) and more primitive 
CD34+38lo (black bars)) after 24h omacetaxine uptake expressed as the total 
percentage of Annexin V+ cells. (a)(ii) Viable cells remaining after 24h 
omacetaxine treatment of sorted CML cell fractions were calculated as the 
product of the percentage Annexin V+ cells times the live (trypan blue negative) 
count and expressed as a percentage of the NDC. (b) Analysis of protein lysates 
from sorted (i) CD34+38+ and more primitive (ii) CD34+38lo CML cell populations 
treated with omacetaxine at indicated time-points demonstrated PARP cleavage 
and reduced expression of Mcl-1 protein in both cell populations after 24h.  
GAPDH was used a loading control for all gels [(i) Mcl1:GAPDH ratio by 
densitometry was 0.881 and 0.248 for 0 and 24h, respectively; (ii) Mcl1:GAPDH 
was 0.528 and 0.272 at 0 and 24h, respectively] . 
 
Supplementary Information accompanies the paper on the Leukemia website 
(http://www.nature.com/leu)  
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